title: Psychoimmunoendocrine aspects of panic disorder.
abstract: Immunological, neuroendocrine and psychological parameters were examined in 14 psychophysically healthy subjects and in 17 panic disorder patients before and after a 30-day course of alprazolam therapy. T lymphocyte proliferation in response to the mitogen phytohemagglutinin, lymphocyte beta-endorphin (beta-EP) concentrations, plasma ACTH, cortisol and beta-EP levels were examined in basal conditions and after corticotropin-releasing hormone (CRH) stimulation. Cortisol inhibition by dexamethasone (DST) and basal growth hormone (GH) and prolactin levels were also examined. Depression, state or trait anxiety, anticipatory anxiety, agoraphobia, simple and social phobias, severity and frequency of panic attacks were monitored by rating scales. The immune study did not reveal any significant difference between patients and controls, or any effect of alprazolam therapy. The hormonal data for the two groups were similar, except for higher than normal basal ACTH and GH plasma levels, lower than normal ratios between the ACTH and cortisol responses to CRH, and blunted DST in some patients. All the impairments improved after alprazolam therapy, in parallel with decreases in anxiety and in severity and frequency of panic attacks.
authors.affiliation: Ospedale Psichiatrico Pini, Istituto Scientifico S. Raffaele, Milano, Italia.
authors.forename: F
authors.initials: F
authors.lastname: Brambilla
authors.forename: L
authors.initials: L
authors.lastname: Bellodi
authors.forename: G
authors.initials: G
authors.lastname: Perna
authors.forename: M
authors.initials: M
authors.lastname: Battaglia
authors.forename: G
authors.initials: G
authors.lastname: Sciuto
authors.forename: G
authors.initials: G
authors.lastname: Diaferia
authors.forename: F
authors.initials: F
authors.lastname: Petraglia
authors.forename: A
authors.initials: A
authors.lastname: Panerai
authors.forename: P
authors.initials: P
authors.lastname: Sacerdote
mesh_terms: D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D000379:Agoraphobia / Q000188:drug therapy / Q000276:immunology / Q000523:psychology; D000525:Alprazolam / Q000008:administration & dosage*; D003346:Corticotropin-Releasing Hormone; D003907:Dexamethasone; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006728:Hormones / Q000097:blood*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000503:physiopathology*; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000188:drug therapy / Q000276:immunology* / Q000523:psychology; D010555:Personality Inventory; D010913:Pituitary-Adrenal System / Q000187:drug effects / Q000503:physiopathology*; D011388:Prolactin / Q000097:blood; D011598:Psychoneuroimmunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D001615:beta-Endorphin / Q000097:blood
chemical_list: D006728:Hormones; D001615:beta-Endorphin; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D013006:Growth Hormone; D003346:Corticotropin-Releasing Hormone; D006854:Hydrocortisone; D000525:Alprazolam